FFR narrows cost gap by limiting repeat revascularization, data show

08/26/2013 | TCTMD.com

Although PCI initially carries higher costs than medical therapy alone for patients with abnormal fractional flow reserve, the difference narrows considerably when first-year follow-up costs are considered, according to FAME 2 data. The study of more than 1,200 patients with stable coronary artery disease and angiographically significant stenoses found those treated with PCI were less likely to need repeat revascularization. Experts said assessing FFR allows clinicians to zero in on functionally significant lesions, and appropriate use criteria should be updated accordingly.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park